Return to homepagePandemic Pact

Repositioning of a potent cyclophilin inhibitor, alisporivir (DEBIO-025), for the antiviral treatment of SARS-CoV-2 infections]

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Other funders (France)

  • Principal Investigator

    Jean-Michel PAWLOTSKY

  • Research Location

    France

  • Lead Research Institution

    Institut Mondor de Recherche Biomédicale

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The CYCLO-CoV project aims to explore the potential efficacy of a promising antiviral compound, alisporivir, against the Sars-CoV-2 virus. Previous studies have shown that alisporivir has activity against certain coronaviruses, and that it is well tolerated by the body: this would make it an interesting candidate for the management of Covid-19. It is also to show that a new family of molecules is active against this virus: it could be used in the future to fight a next pandemic.